MA35364B1 - Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire - Google Patents

Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire

Info

Publication number
MA35364B1
MA35364B1 MA36786A MA36786A MA35364B1 MA 35364 B1 MA35364 B1 MA 35364B1 MA 36786 A MA36786 A MA 36786A MA 36786 A MA36786 A MA 36786A MA 35364 B1 MA35364 B1 MA 35364B1
Authority
MA
Morocco
Prior art keywords
bicyclic heterocyclic
treatment
heterocyclic derivatives
arterial hypertension
pulmonary arterial
Prior art date
Application number
MA36786A
Other languages
English (en)
Inventor
Ian Bruce
Sylvie Chamoin
Stephen Paul Collingwood
Pascal Furet
Vikki Furminger
Sarah Lewis
Jon Christopher Loren
Valentina Molteni
Alex Michael Saunders
Duncan Shaw
Lilya Sviridenko
Christopher Thomson
Vince Yeh
Diana Janus
Ryan West
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47018333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35364(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of MA35364B1 publication Critical patent/MA35364B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des dérivés hétérocycliques bicycliques de formule i utiles dans l'inhibition d'une activité biologique à médiation par un récepteur de pdgf. A est et r1, r1a, r2, r3, r4, r5, r6 et x sont tels que définis présentement.
MA36786A 2011-09-01 2014-02-28 Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire MA35364B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530049P 2011-09-01 2011-09-01
US201261680119P 2012-08-06 2012-08-06
PCT/IB2012/054501 WO2013030802A1 (fr) 2011-09-01 2012-08-31 Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire

Publications (1)

Publication Number Publication Date
MA35364B1 true MA35364B1 (fr) 2014-08-01

Family

ID=47018333

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36786A MA35364B1 (fr) 2011-09-01 2014-02-28 Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire

Country Status (28)

Country Link
US (2) US8883819B2 (fr)
EP (1) EP2751108B1 (fr)
JP (1) JP5815870B2 (fr)
KR (1) KR101687082B1 (fr)
CN (2) CN104024252B (fr)
AP (1) AP3818A (fr)
AR (1) AR087755A1 (fr)
AU (1) AU2012303674B2 (fr)
BR (1) BR112014004631B1 (fr)
CA (1) CA2845753C (fr)
CL (1) CL2014000459A1 (fr)
CO (1) CO6900139A2 (fr)
CR (1) CR20140099A (fr)
EA (1) EA024068B1 (fr)
ES (1) ES2585048T3 (fr)
IL (1) IL231228A0 (fr)
MA (1) MA35364B1 (fr)
MX (1) MX360316B (fr)
PE (1) PE20141674A1 (fr)
PH (1) PH12014500407A1 (fr)
PL (1) PL2751108T3 (fr)
PT (1) PT2751108T (fr)
SG (1) SG11201400253YA (fr)
TN (1) TN2014000067A1 (fr)
TW (1) TW201313718A (fr)
UY (1) UY34305A (fr)
WO (1) WO2013030802A1 (fr)
ZA (1) ZA201401294B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2685903B2 (ja) 1989-07-05 1997-12-08 アルプス電気株式会社 磁気ヘッド支持装置
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (fr) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines comme inhibiteurs de la tryptophan hydroxylase
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
WO2016109501A1 (fr) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Composés amides utilisés en tant qu'inhibiteurs de la tryptophane hydroxylase
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
KR20210102887A (ko) 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
CN119371371A (zh) * 2019-12-13 2025-01-28 日本新药株式会社 作为pdgf受体激酶抑制剂的化合物和组合物
CA3183351A1 (fr) 2020-06-19 2021-12-23 Yale University Polymeres de poly(amine-co-ester) presentant des groupes terminaux modifies et administration pulmonaire amelioree
US20220031633A1 (en) * 2020-07-28 2022-02-03 Yale University Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
AU2021405620A1 (en) 2020-12-23 2023-06-29 Actelion Pharmaceuticals Ltd Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
TW202313053A (zh) 2021-07-30 2023-04-01 瑞士商艾克泰聯製藥有限公司 吡唑并嘧啶及其作為ｐｄｇｆｒ抑制劑之用途
CN113912530A (zh) * 2021-11-10 2022-01-11 山东汇海医药化工有限公司 一种4-aa中间体废液的处理方法
WO2023247593A1 (fr) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrrolopyridine carboxamides et leurs utilisations en tant qu'inhibiteurs de pdgfr
WO2023247595A1 (fr) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolopyrazine carboxamides et leurs utilisations comme inhibiteurs de pdgfr
WO2023247590A1 (fr) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Carboxamides de triazolopyridine et de benzoisoxazole et leurs utilisations en tant qu'inhibiteurs de pdgfr
WO2023247596A1 (fr) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolothiazole carboxamides et leurs utilisations comme inhibiteurs de pdgfr
WO2024104968A1 (fr) 2022-11-14 2024-05-23 Actelion Pharmaceuticals Ltd Pyrazolopyrrolopyridazines et leurs utilisations en tant qu'inhibiteurs de pdgfr
EP4626884A1 (fr) 2022-11-30 2025-10-08 Blueprint Medicines Corporation Dérivés de n-phényl-pyrazolo[1,5-a]pyridine-3-carboxamide utilisés en tant qu'inhibiteurs de kinase c-kit de type sauvage pour le traitement de l'urticaire

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
ZA81219B (en) 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
WO1993019751A1 (fr) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Composes utilisables dans le traitement des maladies inflammatoires et dans l'inhibition de la production du facteur de necrose tumorale
JP3192424B2 (ja) 1992-04-02 2001-07-30 スミスクライン・ビーチャム・コーポレイション アレルギーまたは炎症疾患の治療用化合物
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
US6182655B1 (en) 1995-12-07 2001-02-06 Jago Research Ag Inhaler for multiple dosed administration of a pharmacological dry powder
DK0883415T3 (da) 1996-02-21 2002-08-19 Schering Corp Inhalator til pulverformigt medikament
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
KR100563395B1 (ko) 1998-06-30 2006-03-23 다우 글로벌 테크놀로지스 인크. 중합체 폴리올 및 이의 제조방법
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
BR9912729A (pt) 1998-08-04 2001-05-02 Astrazeneca Ab Derivado de amida, processo para prepará-lo, e, uso do mesmo
EP1163212B1 (fr) 1999-03-17 2005-08-31 AstraZeneca AB Derives amides
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
PL203117B1 (pl) 1999-05-04 2009-08-31 Schering Corp Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
SK286641B6 (sk) 1999-05-04 2009-03-05 Schering Corporation Piperazínové deriváty užitočné ako CCR5 antagonisty, farmaceutické prípravky s ich obsahom a ich použitie
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
HUP0300832A2 (hu) 2000-04-27 2003-08-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
AU2001266100B9 (en) 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
CA2417826A1 (fr) 2000-08-05 2002-02-14 Glaxo Group Limited Derives de 17-beta-carbothioate-17-alpha-arylcarbonyloxyloxy androstane utilises comme anti-inflammatoires
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
EP1345937B1 (fr) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3
SI1353919T1 (sl) 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
AR033290A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
EP1395604B1 (fr) 2001-06-12 2008-06-25 Glaxo Group Limited 17 alpha esters heterocycliques anti-inflammatoires de derives de 17 beta carbothioate androstane
EP2039762A3 (fr) 2001-06-21 2009-07-29 Verenium Corporation Nitralases
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
RU2004110717A (ru) 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
CA2470956C (fr) 2001-12-20 2011-08-02 Laboratorios S.A.L.V.A.T., S.A. Derives de 1-alkyl-1- azoniabicyclo[2.2.2]octane carbamate
AU2003202044A1 (en) 2002-01-15 2003-09-09 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en) 2002-01-21 2003-09-02 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
WO2004078163A2 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
AU2003220190A1 (en) 2002-03-13 2003-09-29 Pharmacia & Upjohn Company Llc Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
JP4324480B2 (ja) 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
EP1490317A1 (fr) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations
WO2003086294A2 (fr) 2002-04-11 2003-10-23 Merck & Co., Inc. Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1507754A1 (fr) 2002-05-28 2005-02-23 Theravance, Inc. Agonistes du recepteur adrenergique beta 2 alcoxy aryle
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
WO2004000814A1 (fr) 2002-06-25 2003-12-31 Merck Frosst Canada & Co. Inhibiteurs de pde4 8-(biaryle)quinolines
US20060004056A1 (en) 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
WO2004005229A1 (fr) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
US20060166995A1 (en) 2002-08-10 2006-07-27 Altana Pharma Ag Piperidine-n-oxide-derivatives
US20060167001A1 (en) 2002-08-10 2006-07-27 Sterk Jan G Pyridazinone-derivatives as pde4 inhibitors
HRP20050198A2 (hr) 2002-08-10 2006-04-30 Altana Pharma Ag Piperidin-piridazoni i ftalazoni kao inhibitori pde4
WO2004018449A1 (fr) 2002-08-10 2004-03-04 Altana Pharma Ag Derives de piperidine utilises comme inhibiteurs de la phospodiesterase-4 (pde4)
CA2495597A1 (fr) 2002-08-17 2004-03-04 Altana Pharma Ag Nouvelles phenanthridines
AU2003263216A1 (en) 2002-08-17 2004-03-11 Nycomed Gmbh Benzonaphthyridines with PDE 3/4 inhibiting activity
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
CA2496175A1 (fr) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
EP1534675B1 (fr) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
AU2003255493B8 (en) 2002-08-29 2009-03-26 Takeda Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
CA2496459C (fr) 2002-08-29 2013-06-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines en tant qu'inhibiteurs de pde-4
NZ538932A (en) 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JPWO2004026873A1 (ja) 2002-09-18 2006-01-19 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
WO2004026867A2 (fr) 2002-09-19 2004-04-01 Schering Corporation Nouvelles imidazopyridines utilisees comme inhibiteurs des kinases dependantes des cyclines
KR20050072090A (ko) 2002-09-19 2005-07-08 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리딘
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
AU2003270783C1 (en) 2002-09-20 2010-05-20 Merck Sharp & Dohme Corp. Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
MXPA05003866A (es) 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
EP1440966A1 (fr) 2003-01-10 2004-07-28 Pfizer Limited Dérivés d'indole utilisables pour traiter des maladies
AU2003298094A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Medicinal arylethanolamine compounds
KR20050065624A (ko) 2002-10-23 2005-06-29 그렌마크 파머수티칼스 엘티디. 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
DE60320007T2 (de) 2002-10-28 2009-06-18 Glaxo Group Ltd., Greenford Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
AU2004207482B2 (en) 2003-01-21 2009-10-08 Merck Sharp & Dohme Corp. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1460064A1 (fr) 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
PL377633A1 (pl) 2003-04-03 2006-02-06 Merck Patent Gmbh Związki karbonylowe
EP1479680A1 (fr) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Derivés d' azaindole en tant qu'inhibiteurs du facteur Xa
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
EP1636269A2 (fr) 2003-06-10 2006-03-22 Ace Biosciences A/S Polypeptides d'aspergillus extracellulaires
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005048953A2 (fr) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Derives d'amide utilises comme modulateurs de la kinase
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
TW200634003A (en) 2004-12-22 2006-10-01 Astrazeneca Ab Chemical compounds
KR100919905B1 (ko) 2005-01-26 2009-10-06 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
AR056187A1 (es) 2005-03-21 2007-09-26 S Bio Pte Ltd Derivados de imidazo[1,2-a)piridina: preparacion, composiciones farmaceuticas y uso para preparar medicamentos
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
WO2007017143A1 (fr) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Derives de l'azabenzimidazole, leur fabrication et leur utilisation en tant qu'agents anticancereux
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
CA2621983A1 (fr) 2005-09-09 2007-03-22 Schering Corporation Nouveaux derives 4-cyano, 4-amino, et 4-aminomethyl des composes pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine et 2h-indazole, et nouveaux derives 5-cyano, 5-amino, et 5-aminomethyl des composes imidazo[1,2-a]pyridine, et imidazo[1,5-a]pyrazine pouvant servir d'inhibiteurs d
US7795273B2 (en) 2005-12-08 2010-09-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
JP2009523845A (ja) * 2006-01-23 2009-06-25 クリスタルゲノミクス インコーポレーテッド たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物
GB0604937D0 (en) 2006-03-10 2006-04-19 Novartis Ag Organic compounds
JP2009531390A (ja) 2006-03-31 2009-09-03 ノバルティス アクチエンゲゼルシャフト 有機化合物
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
BRPI0716477A2 (pt) * 2006-09-06 2014-03-18 Hoffmann La Roche Derivados heteroarila como inibidores de quinase protéica
EA200970447A1 (ru) 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
WO2008086014A2 (fr) 2007-01-09 2008-07-17 Amgen Inc. Dérivés de bis-aryl amide et procédés d'utilisation
WO2008134553A1 (fr) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Procédés de traitement de maladies associées aux canaux sodiques au moyen de composés bicycliques
WO2008144253A1 (fr) 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
CA2691987C (fr) 2007-06-12 2016-08-16 Achaogen, Inc. Agents antibacteriens
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2009086277A1 (fr) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Benzènes tétrasubstitués
WO2009103778A1 (fr) 2008-02-19 2009-08-27 Novasaid Ab Composés et procédés
CA2722418C (fr) 2008-05-13 2013-09-17 Irm Llc Heterocycles fusionnes contenant de l'azote et compositions a base de ceux-ci utilisees comme inhibiteurs de kinase
CA2732520A1 (fr) 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Composes therapeutiques
EP2210891A1 (fr) 2009-01-26 2010-07-28 Domain Therapeutics Nouveaux ligands du récepteur de l'adénosine et leurs utilisations
WO2010088000A2 (fr) 2009-02-02 2010-08-05 Angion Biomedica Corp. Composés antifibrotiques et leurs utilisations
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
WO2011050245A1 (fr) 2009-10-23 2011-04-28 Yangbo Feng Hétéroaryles bicycliques formant inhibiteurs de la kinase
EP2937345B1 (fr) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase raf de type ii
WO2011156655A2 (fr) 2010-06-09 2011-12-15 Receptos, Inc. Nouveaux stabilisants et modulateurs de récepteur glp-1
BR112013000946B1 (pt) 2010-07-14 2020-09-08 Novartis Ag Compostos heterocíclicos agonistas de receptor de ip, seus usos, composição e combinação farmacêuticas
WO2012017021A2 (fr) * 2010-08-03 2012-02-09 Graffinity Pharmaceuticals Gmbh Ligands pour la purification d'anticorps et de protéine de fusion à fc par chromatographie d'affinité
US8809541B2 (en) 2010-08-25 2014-08-19 Neopharm Co., Ltd. Heterocyclic compound, and composition for treating inflammatory diseases using same
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
US8883819B2 (en) * 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension

Also Published As

Publication number Publication date
CN104024252B (zh) 2015-08-26
PE20141674A1 (es) 2014-11-14
JP5815870B2 (ja) 2015-11-17
ES2585048T3 (es) 2016-10-03
US9751876B2 (en) 2017-09-05
BR112014004631B1 (pt) 2020-02-11
NZ621436A (en) 2015-10-30
KR101687082B1 (ko) 2016-12-15
ZA201401294B (en) 2015-06-24
US8883819B2 (en) 2014-11-11
CN104024252A (zh) 2014-09-03
JP2014527544A (ja) 2014-10-16
HK1196126A1 (zh) 2015-03-20
AP3818A (en) 2016-09-30
WO2013030802A1 (fr) 2013-03-07
PH12014500407A1 (en) 2017-04-07
AP2014007539A0 (en) 2014-03-31
US20130237519A1 (en) 2013-09-12
MX360316B (es) 2018-10-29
KR20140059272A (ko) 2014-05-15
EP2751108B1 (fr) 2016-04-27
MX2014002499A (es) 2014-05-30
UY34305A (es) 2013-04-30
AU2012303674B2 (en) 2015-11-26
TW201313718A (zh) 2013-04-01
AU2012303674A1 (en) 2014-03-13
IL231228A0 (en) 2014-04-30
CN105001218B (zh) 2017-04-12
TN2014000067A1 (en) 2015-07-01
CO6900139A2 (es) 2014-03-20
PL2751108T3 (pl) 2016-11-30
CA2845753A1 (fr) 2013-03-07
EA024068B1 (ru) 2016-08-31
CA2845753C (fr) 2021-04-20
AR087755A1 (es) 2014-04-16
BR112014004631A2 (pt) 2017-03-14
EA201490543A1 (ru) 2014-07-30
CR20140099A (es) 2014-06-25
US20150025059A1 (en) 2015-01-22
CL2014000459A1 (es) 2014-09-05
EP2751108A1 (fr) 2014-07-09
CN105001218A (zh) 2015-10-28
PT2751108T (pt) 2016-08-04
SG11201400253YA (en) 2014-03-28

Similar Documents

Publication Publication Date Title
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA35285B1 (fr) Indazoles
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA31373B1 (fr) Composes amino-heterocycliques
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA201071370A1 (ru) Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA32231B1 (fr) Composés organiques
ATE538099T1 (de) 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
EA200702471A1 (ru) Новые гетероциклические соединения в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
BR112014004631A2 (pt) derivados de heterociclo bicíclico para o tratamento de hipertensão arterial pulmonar
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
MA35032B1 (fr) Derives de glycoside et leurs utilisations dans le traitement du diabete
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA32108B1 (fr) Derives d'indazole